# US 2003/0207889 A1 · Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0207889 A1
- Document ID: US20030207889A1
- Status: Published application
- Kind: A1
- Application number: 10/425,307
- Filed: 2003-04-29
- Published: 2003-11-06
- Earliest claimed: 1996-08-07
- Inventors: David Alan Owen; John Gary Montana; John Fraser Keily; Robert John Watson; Andrew Douglas Baxter
- Web page: https://patentgrep.com/patent/US20030207889A1

## CPC

- C07D 207/48: Sulfur atoms
- C07C 317/44: having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C 2601/08: the ring being saturated
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity.

## Claims

### Claim 1

A compound of formula (Ic)
B—SO2—CH2—CHR1—CO—NHOH (Ic)
wherein
R1 is C1-6 alkyl substituted with R9;
B is aryl or heteroaryl, either of which is optionally substituted by a substituent selected from R5, C1-6 alkyl-R5, C2-6 alkenyl-R5, aryl (optionally substituted with R5), aryl-C1-6 alkyl-R5, C1-6 alkyl-aryl (optionally substituted with R5), C1-6 alkyl-heteroaryl (optionally substituted with R5), aryl-C2-6 alkenyl-R7, heteroaryl (optionally substituted with R5), heteroaryl-C1-6 alkyl-R5, cycloalkyl (optionally substituted with R5), benzofused cycloalkyl (optionally substituted with R5), heterocycloalkyl (optionally substituted with R5), benzofused heterocycloalkyl (optionally substituted with R5), and the groups:
15
R2 is H or C1-6 alkyl;
R5 is C1-6 alkyl, C2-6 alkenyl-R7, halogen, CN, NO2, N(R6)2, OR6, COR6, CO2R2, CON(R6)2, NR6R7, S(O)0-2R8 or SO2N(R6)2;
R6 is H or a group selected from C1-6 alkyl, aryl, C1-6 alkyl-aryl, heteroaryl, C1-6 alkyl-heteroaryl, cycloalkyl, C1-6 alkyl-cycloalkyl, heterocycloalkyl and C1-6 alkyl-heterocycloalkyl, wherein said group is optionally substituted with R8, COR8, SO0-2R8, CO2R8, OR8, CONR2R8, NR2R8, halogen, CN, SO2NR2R8 or NO2, and for each case of N(R6)2 the R6 groups are the same or different or N(R6)2 is heterocycloalkyl optionally substituted with R8, COR8, SO0-2R8, CO2R8, OR8, CONR2R8, NR2R8, halogen, CN, SO2NR2R8 or NO2;
R7 is COR6, CON(R6)2, CO2R8 or SO2R8;
R8 is C1-6 alkyl, aryl, C1-6 alkyl-aryl, heteroaryl or C1-6 alkyl-heteroaryl; and
R9 is phthalimido, succinimido or the group:
16
or an N-oxide, salt, solvate, hydrate, protected amino or protected carboxy derivative thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R1 is ethyl or propyl.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R2 is methyl.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein B is optionally substituted phenyl, furanyl, thiophenyl, pyridyl or pyridyl-N-oxide.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein R5 is OR6 or COR6.

### Claim 6 (depends on 5)

The compound according to claim 5, wherein R6 is optionally substituted C1-6 alkyl, aryl, C1-6 alkyl-aryl, heteroaryl or C1-6 alkyl-heteroaryl.

### Claim 7 (depends on 6)

The compound according to claim 6, wherein R6 is optionally substituted methyl, phenyl, furanyl, thiophenyl, pyridyl, pyridyl-N-oxide, methyl-pyridyl, ethyl-pyridyl, methyl-furanyl, ethyl-furanyl, methyl-thiophenyl or ethyl-thiophenyl.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein R6 is substituted with R8, OR8, F, Cl, Br, I or CN.

### Claim 9 (depends on 8)

The compound according to claim 8, wherein R6 is substituted with phenyl, OCH3 or Cl.

### Claim 10 (depends on 1)

The compound according to claim 1, selected from the group consisting of:
2-(4-Methoxyphenylsulfonylmethyl)-5-phthalimido-pentanoic Acid N-Hydroxy Amide;
2-(4-Methoxyphenylsulfonylmethyl)-4-phthalimido-butanoic Acid N-Hydroxy Amide;
2-(4-Methoxyphenylsulfonylmethyl)-5-succinimido-pentanoic Acid N-Hydroxy Amide;
2-(4-Benzoylphenyl)sulfonylmethyl-5-succinimido-pentanoic Acid N-Hydroxy Amide;
2-(4-Methoxyphenylsulfonylmethyl)-5-(3,3,4-trimethylhydantoin-1-yl)pentanoic Acid N-Hydroxy Amide;
2-(4-Methoxyphenylsulfonylmethyl)-4-(3,3,4-trimethylhydantoin-1-yl)butanoic Acid N-Hydroxy Amide;
2-((4-Trifluoromethoxyphenylsulfonyl)methyl)-5-(1,5,5-trimethylhydantoin-3-yl)pentanoic Acid N-Hydroxy Amide;
2-(4-benzoylphenyl)sulfonylmethyl-4-(3,3,4-trimethylhydantoin-1-yl)butanoic Acid N-Hydroxy Amide;
2-((4-Benzoylphenyl)sulfonylmethyl)-5-(3,3,4-trimethylhydantoin-1-yl)pentanoic Acid N-Hydroxy Amide;
2-((4-(4-Pyridinoyl)phenyl)sulfonylmethyl)-5-(3,3,4-trimethylhydantoin-1-yl)pentanoic Acid N-Hydroxy Amide;
2-((4-(2-Thienoyl)phenyl)sulfonylmethyl)-5-(3,3,4-trimethylhydantoin-1-yl)pentanoic Acid N-Hydroxy Amide; and
2-(1-Oxy-pyridine-4-sulfonylmethyl)-5-(3,4,4-trimethyl-2,5-dioxo-imidazolidin-1-yl)pentanoic acid hydroxyamide.

### Claim 11 (depends on 1)

A method for the treatment or prevention of a condition associated with matrix metalloproteinases or that is mediated by TNF α or enzymes involved in the shedding of L-selectin, the TNF receptors or IL-6 receptors, which comprises administration of a compound of claim 1 to a patient in need thereof.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the condition is selected from the group consisting of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response, cachexia, anorexia, acute infection, HIV infection, shock states, graft versus host reactions, autoimmune disease, reperfusion injury, meningitis, migraine, and aspirin-independent anti-thrombosis.

### Claim 13 (depends on 11)

The method according to claim 11, wherein the condition is selected from the group consisting of tumour growth, angiogenesis, tumour invasion and spread, metastases, malignant ascites, and malignant pleural effusion.

### Claim 14 (depends on 11)

The method according to claim 11, wherein the condition is selected from the group consisting of cerebral ischaemia, ischaemic heart disease, rheumatoid arthritis, osteoarthritis, osteoporosis, asthma, multiple sclerosis, neurodegeneration, Alzheimer's, atherosclerosis, stroke, vasculitis, Crohn's disease, and ulcerative colitis.

### Claim 15 (depends on 11)

The method according to claim 11, wherein the condition is selected from the group consisting of corneal ulceration, retinopathy, and surgical wound healing.

### Claim 16 (depends on 11)

The method according to claim 11, wherein the condition is selected from the group consisting of psoriasis, atopic dermatitis, chronic ulcers, and epidermolysis bullosa.

### Claim 17 (depends on 11)

The method according to claim 11, wherein the condition is selected from the group consisting of periodontitis, and gingivitis.

### Claim 18 (depends on 11)

The method according to claim 11, wherein the condition is selected from the group consisting of rhinitis, allergic conjunctivitis, eczema, and anaphylaxis.

### Claim 19 (depends on 11)

The method according to claim 11, wherein the condition is selected from the group consisting of restenosis, congestive heart failure, endometriosis, atherosclerosis, and endosclerosis.
